Please assess the completion status of the following clinical trial:

Trial Title: Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* From 2 up to and including 13 years of age~* Clinical and laboratory confirmed diagnosis of HAE (baseline C1INH activity \<50% of normal)~* Signed written Informed Consent Form (ICF)(parental permission) signed by the legal guardian(s)~* Clinical symptoms of an acute HAE attack~* Onset of eligible symptoms within 5 hours from the moment at which medical evaluation to determine eligibility has occurred~* Attack severity moderate or greater, as rated by the investigator~Exclusion Criteria:~* A diagnosis of acquired C1INH deficiency (AAE)~* A medical history of allergy to rabbits or rabbit-derived products or positive anti-rabbit epithelium (dander) immunoglobuline E (IgE) test

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 13 Years
- Healthy Volunteers: f

Study Arms:
- Recombinant Human C1 Inhibitor (Type: EXPERIMENTAL): Patients presented to the clinic within 5 hours of onset received rhC1INH 50 U/kg body weight up to a maximum of 4200 U.

Based on this trial design, predict the completion outcome and termination type (if applicable).